SCHEMBL1989005

SCHEMBL1989005

O=C(N[C@H]1CCCC(F)(F)[C@H]1NC(=O)OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.51
ALDH1A1 P00352 2/20 0.50
KDM1A O60341 1/20 0.50
MAOB P27338 1/20 0.50
GAA P10253 1/20 0.50
CPB1 P15086 2/20 0.49
CASP3 P42574 3/20 0.48
TSHR P16473 1/20 0.48
CTSB P07858 3/20 0.45
CTSK P43235 3/20 0.45
CTSS P25774 2/20 0.45
CTSL P07711 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
DPP4 P27487 1/20 0.45
KCNH2 Q12809 1/20 0.45
DPP7 Q9UHL4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178107 1.00 EPHX1 (0.51) EPHX1ALDH1A1KDM1AMAOBGAA
SCHEMBL12640900 1.00 EPHX1 (0.51) EPHX1ALDH1A1KDM1AMAOBGAA
SCHEMBL12564554 1.00 EPHX1 (0.51) EPHX1ALDH1A1KDM1AMAOBGAA
SCHEMBL1989006 1.00 EPHX1 (0.51) EPHX1ALDH1A1KDM1AMAOBGAA
SCHEMBL28377094 0.92 CPB1 (0.45) EPHX1ALDH1A1KDM1AMAOBGAA
SCHEMBL28380522 0.92 CPB1 (0.45) EPHX1ALDH1A1KDM1AMAOBGAA
SCHEMBL27301394 0.88 ALDH1A1 (0.50) EPHX1ALDH1A1KDM1AMAOBGAA
SCHEMBL28380424 0.87 ALDH1A1 (0.52) EPHX1ALDH1A1KDM1AMAOBGAA
Hydrochloric Acid SCHEMBL28376398 0.86 ALDH1A1 (0.51) EPHX1ALDH1A1KDM1AMAOBGAA
SCHEMBL6612597 0.81 EPHX1 (0.63) EPHX1ALDH1A1GAACPB1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 US disclosed
EP-3825316-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2021-05-26 EP disclosed
EP-3489236-B1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICALS CO (JP) 2020-09-30 EP disclosed
EP-3489236-A1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES Takeda Pharmaceutical Company Limited (JP) 2019-05-29 EP disclosed
EP-2902392-B1 Fused heteroaromatic pyrrolidinones as syk inhibitors TAKEDA PHARMACEUTICALS CO (JP) 2018-10-17 EP disclosed
US-20180141951-A1 FUSED HETEROAROMATIC PYRROLIDINONES CALITHERA BIOSCIENCES, INC. 2018-05-24 US disclosed
US-20150336964-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-26 US disclosed
US-9181255-B2 Fused heteroaromatic pyrrolidinones as SYK inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 US disclosed
US-9108970-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-08-18 US disclosed
EP-2902392-A1 Fused heteroaromatic pyrrolidinones as syk inhibitors Takeda Pharmaceutical Company Limited (JP) 2015-08-05 EP disclosed
EP-2516434-B1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-05-27 EP disclosed
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2013-09-19 US disclosed
US-8440689-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-14 US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 US disclosed
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141951-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN EPHX1 1647/4885ALDH1A1 824/4885KDM1A 601/4885
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS SYK, BTK, LYN EPHX1 1609/4885ALDH1A1 1660/4885KDM1A 357/4885
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN EPHX1 1647/4885ALDH1A1 824/4885KDM1A 601/4885
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN EPHX1 1647/4885ALDH1A1 824/4885KDM1A 601/4885
US-20150336964-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN EPHX1 1647/4885ALDH1A1 824/4885KDM1A 601/4885
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN EPHX1 1647/4885ALDH1A1 824/4885KDM1A 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.